Eli Lilly announced a planned increase in the list prices of its weight-loss drug Mounjaro across Europe, including a 170% hike in the United Kingdom, aligning pricing closer to US levels. This strategy follows pressure from the Trump administration advocating for fairer cost sharing of pharmaceutical innovation across developed markets through most-favored-nation policies. Lilly maintains UK National Health Service prices will remain unchanged and emphasizes commitment to sustaining US drug research.